PT  - JOURNAL ARTICLE
AU  - Clara M Castillejo Becerra
AU  - Yue Ding
AU  - Beatrice Kenol
AU  - Andrew Hendershot
AU  - Alexa Simon Meara
TI  - Ocular side effects of antirheumatic medications: a qualitative review
AID  - 10.1136/bmjophth-2019-000331
DP  - 2020 Jan 01
TA  - BMJ Open Ophthalmology
PG  - e000331
VI  - 5
IP  - 1
4099  - http://bmjophth.bmj.com/content/5/1/e000331.short
4100  - http://bmjophth.bmj.com/content/5/1/e000331.full
SO  - BMJ Open Ophth2020 Jan 01; 5
AB  - Topic This paper reviews the ocular side effects of medications used in the treatment of rheumatological conditions.Clinical relevance Rheumatic diseases are inflammatory conditions that may affect the skin, blood vessels, joints, muscles and internal organs. Immunosuppressive agents are often used as treatment and while powerful, they carry side effects and toxicities that need careful monitoring. Ophthalmic complications have been reported with the use of antirheumatic medications; however, there is a lack of literature synthesising these reports. This paper addresses this gap and hopes to inform both rheumatologists and ophthalmologists as they work together on the management of patients with rheumatological conditions.Methods PubMed literature search was conducted from November to September 2019 searching for ocular side effects with the use of 25 rheumatological drugs.Results A total of 111 papers were included in this review. Adverse side effects were divided into non-infectious and infectious causes. Traditional disease-modifying antirheumatic drugs (DMARDs) were associated with pruritus, irritation and dryness of the conjunctiva while biologic DMARDS showed reports of new-onset/recurrent uveitis and demyelinating conditions. Infectious side effects included episodes of cytomegalovirus retinitis, toxoplasmic chorioretinitis and endophthalmitis. Other serious side effects were encountered and included in this review.Conclusion The goal of this paper is to inform healthcare providers about potential ocular side effects from rheumatological medications. Healthcare providers are encouraged to learn more about these ophthalmic complications and find relevance within their clinical practice.